Business Context and Reporting Period
This Form 8-K, dated August 12, 2026, reports a material definitive agreement entered into by Skye Bioscience, Inc. (Skye) on August 14, 2026. The Company has agreed to acquire Redx Pharma Limited (Redx) via a scheme of arrangement. The filing also details a concurrent financing package, a 1-for-8 reverse stock split to regain Nasdaq compliance, and executive separation agreements.
Key Financial Metrics and Transaction Structure
- Transaction Valuation: Skye is valued at $14.5 million (subject to a $2.0 million floor) and Redx at $125.0 million.
- Concurrent Financing: Skye agreed to raise $67.9 million, potentially increasing to $72.9 million, through a Securities Purchase Agreement.
- Equity Line of Credit (ELOC): A committed facility of up to $22.0 million with Redmile Group, LLC, subject to reduction if financing proceeds exceed $103.0 million.
- Warrant Issuance: A warrant to purchase up to $5.0 million of stock issued to an accredited investor.
- Pro Forma Ownership: Post-transaction, Redx equityholders are expected to own ~46.17%, Skye legacy equityholders ~5.38%, and new investors ~48.45%.
- Reverse Stock Split: A 1-for-8 split is effective August 24, 2026, reducing authorized shares to 37.5 million and outstanding shares to approximately 4.43 million.
Material Changes and Management Transition
The transaction represents a change of control for Skye. Upon closing, current Skye executive officers and directors are expected to tender their resignations. Redx management will assume leadership of the combined company:
- Lisa Anson: Chief Executive Officer
- Peter Collum: Chief Financial Officer
- Mei Lun Wang: Chief Medical Officer
- Dr. Caroline Phillips: Chief Scientific Officer
- Dr. Cliff Jones: Chief Technical Officer
Legacy Skye shareholders will receive Contingent Value Rights (CVRs) entitling them to 90% of net proceeds from the disposition of certain pre-merger assets. Redx shareholders will receive CVRs for 100% of net proceeds from their pre-merger assets.
Guidance, Risks, and Contingencies
Conditions to Closing: The transaction is subject to shareholder approvals from both companies, court sanction of the Scheme of Arrangement, receipt of at least $67.9 million in financing, and Skye maintaining at least $1.0 million in net cash at closing. Closing cannot occur before October 31, 2026, unless a "Specified Adjustment" is resolved.
Termination Fees: A termination fee equal to 3% of the combined company valuation is payable by either party under specific circumstances, such as accepting a superior proposal or failing to obtain shareholder approval.
Executive Separation: Punit Dhillon (CEO) and Tu Diep have entered separation agreements. Dhillon's last day is August 31, 2027, with reduced severance and potential health benefit payments. Diep's last day is January 31, 2027, with salary continuation and a $20,000 lump sum.
Risks: Risks include failure to obtain regulatory or shareholder approval, inability to secure financing, failure to integrate operations, and the possibility that CVR holders receive no payments if asset dispositions do not generate proceeds.
Investor Verification Checklist
- Verify the final amount of the Concurrent Financing and whether the $22.0 million ELOC remains fully available or is reduced based on proceeds.
- Confirm the resolution of the "Specified Adjustment" to ensure the Skye valuation does not drop to the $2.0 million floor.
- Monitor the status of the 1-for-8 reverse stock split and the subsequent trading price to ensure compliance with Nasdaq Rule 5550(a)(2).
- Review the upcoming Proxy Statement for detailed terms of the CVR agreements and the specific assets eligible for future payments.
- Track the timeline for the High Court of Justice of England and Wales to sanction the Scheme of Arrangement.